Berlin (Germany) and Germantown, MD (U.S.A.), November 14, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that Greg Hamilton, Chief Executive Officer, will participate in the following investor conferences:
-Canaccord Genuity Medical Technologies & Diagnostics Forum, Thursday November 17, 2016, New York, Westin New York Grand Central, Presentation: 10:00 am (EST)
-German Equity Forum 2016, Tuesday, November 22, 2016, Frankfurt, Sheraton Frankfurt Airport Hotel, Presentation: 5:00 PM (CET)
-goetzpartners Interdisciplinary Oncology Insight Symposium, November 29, 2016, London, Le Meridien Piccadilly, Panel discussion: 2:00 PM (GMT)
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Contact Epigenomics AG
Vice President Corporate Communications & Investor Relations
Phone +49 (0) 30 24345 386